MINISTRY OF HEALTH

PHARMACY AND POISONS BOARD

Technical Documents (including the Technical Master File/s, Module 3.2.S) for Blood, Blood Components, Plasma derived products and Haematopoietic Progenitor Cells

Application Form for a Product Licence

First Edition, 2016

TABLE OF CONTENTS

MODULE 1: ADMINISTRATIVE INFORMATION AND PRODUCT INFORMATION

1.1 Comprehensive table of contents for all modules

1.2 Cover letter

1.3 Comprehensive table of content

1.4 Application form

Provide a confirmation that the application form is dully filled with relevant information and attachments, dated signed and stamped appropriately.

1.5 Product Information

1.5.1 Prescribing information (Summary of Product Characteristics)

1.5.2 Container labeling

1.5.3 Prescribers insert

1.5.4 Mock-ups and specimens

1.6 Certificates of Suitability of monographs of the European pharmacopoeia (CEP)

1.7 Good Manufacturing Practice (GMP)

1.8 Good Clinical Practice (GCP) and Good Clinical Laboratory Practice (GCLP)

1.9 Regulatory status

1.9.1 Registration status from countries with Stringent Drug Regulatory Authorities (SDRAs)

1.9.2 List of countries in which a similar application has been submitted

1.9.3 Statement on whether an application for the product has been previously rejected, withdrawn or repeatedly deferred in any country

1.10 Manufacturing and Product Licence

1.10.1 Manufacturising Authorisation from country of origin

1.10.2 Product Licence from country of origin (COPP)

1.11 Product samples

1.12 Pre-registration analysis certificate

MODULE 2: OVERVIEW & SUMMARIES

2.1 Table of contents of Module 2
2.2 TD Introduction
2.3 Quality overall summary (QOS)
2.3. S Active Blood Component/ derivatives (ABC/D)
2.3. S.1 General Information
2.3.S.1.1 Name of the Active Blood Component/Derivative
3.2.S.1.3 General properties
2.3.S.2 Manufacture
2.3.S.2.1 Manufacturer/facility (s)
2.3.S.2.2.1: Donor selection and assessment
2.3.S.2.2.1.1 Where applicable to the product, Provide a summary of all matters relating to:Donor selection acceptance criteria, Deferral, Quantity of donation, Donation interval, and Follow up tests after donation.
2.3.S.2.2.1.2: Provide a summary of the Donor identification as included in section 3.2.S.2.2.1.2.
2.3.S.2.2.1.3: Provide a summary of the process of notification and referral of donors (if applicable) as included in section 3.2.S.2.2.1.3.
2.3.S.2.2.1.4: Provide a summary of the detail for Re-admission criteria of a previously temporarily deferred donor (if applicable) as included in section 3.2.S.2.2.1.4.
2.3.S.2.2.2 Donor testing
Provide a summary of the Product dossier to describe the complete regimen of donor testing performed as included in section 3.2.S.2.2.2.
2.3.S.2.2.2.1 Provide a summary of the list of mandated and non-mandated laboratory tests, the purpose of each and their limitations as included in section 3.2.S.2.2.2.1.
2.3.S.2.2.2.2: Provide a summary of the Criteria for acceptance or rejection of donation and re-testing policy as included in section 3.2.S.2.2.2.2.
2.3.S.2.2.2.3 Provide a summary of the relevant information (Exemptions)
2.3.S.2.3 Control of materials
2.3.S.2.4 Controls of critical steps and intermediates

2.3.S.2.5 Process validation and/or evaluation

2.3.S.3 Characterization

2.3.S.3.1 Elucidation of molecular weight and other characteristics

2.3.S.3.2 Impurities

2.3.S.4 Control of the Active Blood Components/Derivatives (ABC/D

2.3.S.5 Reference standards or materials (Where applicable)

2.3.S.6 Container Closure System

2.3.S.7 Stability (if applicable)

2.3.P Final Blood product (FBP)

2.3. P.1 Description and Composition of the dosage form

2.3.P.2 Pharmaceutical Development

2.3.P.3 Manufacture of FBP
2.3.P.3.1 Manufacturer/facility (s) (name, physical address)

2.3.P.3.2 Batch formula

2.3.P.3.3 Description of manufacturing process and process controls

2.3.P.3.4 Controls of critical steps and intermediates
3.2.P.3.5 Process validation and/or evaluation

2.3.P.4 Control of Materials/ Non active Components

2.3.P.5 Control of Final Blood Product

2.3.P.6 Reference Standards or Materials

2.3.P.7 Container Closure System

2.3.P.8 Stability

2.4 Non-Clinical overview (Where applicable)

2.5. Clinical overview
2.5.1 Provide a brief summary of the Clinical indications/clinical outcomes/adverse reactions of the FBP, as described in section 5.3.
2.5.1.2 Provide a brief summary of the relevant clinical practice guidelines on the use of the FBP, as described in section 5.3.
2.5.1.3 Provide a brief summary of the procedure to obtain post product release data following the transplant or transfusion of FBP, as described in section 5.3.
2.5.1.4 Provide a brief summary of the details on the procedures for monitoring an adverse reaction (if applicable), as described in section 5.3.

MODULE 3: QUALITY

1.1 Table of contents of Module 3

1.2 Body of data

3.2. S Active Blood Component/ derivatives (ABC/D)

a) Option 1: Full details in the Product Dossier (PD)
b) Option 2: Certificate of suitability of European Pharmacopeia(CEP)

a) Option 1: Full details by completing Section 3.2.S.1 - 3.2.S.7 of these guidelines

3.2.S.1 General information

3.2.S.1.1 Name of the Active Blood Component/Derivative

3.2.S.1.3 General properties

Physical description

3.2.S.2 Manufacture

3.2.S.2.1 Manufacturer/facility (s) (name, physical address)

3.2.S.2.2 Description of Collection, manufacturing process and process controls

3.2.S.2.2.1 Donor selection and assessment
3.2.S.2.2.1.1 Where applicable to the product, a TMF should describe all matters relating to: donor selection acceptance criteria, deferral, quantity of donation, donation interval, and follow up tests after donation.
The processes used to ensure ability to donate, compatibility with the recipient (if applicable) and exclusion of the risk of disease transmission should be described.
3.2.S.2.2.1.2 Donor identification should be detailed so that all donors are positively verified at critical steps.
3.2.S.2.2.1.3 The process of referral of donors (if applicable) should be detailed to provide information relating to donor and recipient planning.
3.2.S.2.2.1.4 Re-admission criteria of a previously temporarily deferred donor should be provided (if applicable).
3.2.S.2.2.2 Donor testing
3.2.S.2.2.2.1 A list of mandated and non-mandated laboratory tests, the purpose of each and their limitations.
3.2.S.2.2.2.2 Criteria for acceptance or rejection of donation and re-testing policy.
3.2.S.2.2.2.3 The relevant information which the manufacturer is required to submit in support of any exemptions sought under Cap 244.

3.2.S.2.3 Control of materials

3.2.S.2.4 Controls of critical steps and intermediates

3.2.S.2.5 Process validation and/or evaluation

3.2.S.3 Characterization

3.2.S.3.1 Elucidation of molecular weight and other characteristics

3.2.S.3.2 Impurities

3.2.S.4 Control of the Active Blood Components/Derivatives (ABC/D

3.2.S.4.1 Specification

3.2.S.4.2 Analytical procedures

3.2.S.4.3 Validation of analytical procedures

3.2.S.4.4 Batch analyses (if applicable)

3.2.S.4.5 Justification of specification

3.2.S.5 Reference standards or materials (Where applicable)

3.2.S.6 Container-closure system

3.2.S.7 Stability (if applicable)

B. Option 2: Certificate of suitability of European Pharmacopeia (CEP)

A complete copy of the CEP (including any annexes) should be provided in *Module 1.* The declaration of access for the CEP should be dully filled out by the CEP holder on behalf of the FBP manufacturer/facility or applicant to PPB who refers to the CEP.

In addition, a written commitment should be included that the applicant will inform PPB in the event that the CEP is withdrawn. It should also be acknowledged by the applicant that withdrawal of the CEP will require additional consideration of the ABC/D data requirements to support the PD. The written commitment should accompany the copy of the CEP in *Module 1*.

Along with the CEP the applicant should supply the following information in the dossier, with data summarized in the QOS-PD:-

a) *3.2.S.1.3 General properties*

b) *3.2.S.3.1 Elucidation of molecular weight and other characteristics*

c) *3.2.S.4.1 Specification*

d) *3.2.S.4.2/3.2.S.4.3*. Analytical procedures

e) *3.2.S.4.4 Batch analysis* (where applicable)

f) *3.2.S.5 Reference standards or materials*
g) *3.2.S.6 Container-closure system*

h) *3.2.S.7 Stability*

i) Data on the sterilization process of the ABC/D, including validation data, should be included in the Product Dossier (PD).

3.2.P Final Blood product (FBP)

3.2. P.1 Description and Composition of the FBP

1. Description of the dosage form

2. Composition

- **Description of accompanying reconstitution diluent(s), if applicable**

- **Type of container and closure used for the dosage form and accompanying reconstitution diluent, if applicable**

3.2.P.2 Pharmaceutical development (if applicable)

3.2.P.2.1 Components of the FBP

3.2.P.2.1.1 Active Blood Component/derivative

3.2.P.2.1.2 Materials (Non Active Components)

3.2.P.2.2 Finished blood product Formulation Development

3.2.P.2.2.1 Formulation development

3.2. P.2.2.2 Biological properties

3.2.P.2.3 Manufacturing process development

3.2.P.2.4 Container-closure system

3.2.P.2.5 Microbiological attributes

3.2.P.2.6 Compatibility

3.2.P.3 Manufacture of FBP

3.2.P.3.1 Manufacturer/facility (s) (name, physical address)

3.2.P.3.2 Batch formula

3.2.P.3.3 Description of manufacturing process and process controls

3.2.P.3.4 Controls of critical steps and intermediates

3.2.P.3.5 Process validation and/or evaluation

3.2.P.4 Control of Materials/ Non active Components

3.2.P.4.1 Specifications

3.2.P.4.2 Analytical procedures

3.2.P.4.3 Validation of analytical procedures

3.2.P.4.4 Justification of specifications

3.2.P.4.5 Materials of human or animal origin

3.2.P.4.6 Novel Materials

3.2.P.5 Control of FBP

3.2.P.5.1 Specification(s)

3.2.P.5.2 Analytical procedures

3.2.P.5.3 Validation of analytical procedures

3.2.P.5.4 Batch consistency and analysis analyses (where applicable)

3.2.P.5.5 Characterisation/determination of impurities(s)

3.2.P.5.6 Justification of specification(s)

3.2.P.6 Reference standards or materials

3.2.P.7 Container-closure system

Suitability information should be located in 3.2.P.2.

3.2.P.8 Stability

3.2.P.8.1 Stability Summary and Conclusion

3.2.P.8.2 Stability protocol

3.2.P.8.3 Stability Data

3.2.P.8.4 Storage conditions and management of non-conforming and contaminated (viral/microbiological), products should be detailed.
3.2.P.8.5 Description of validated protocols (product stability during transport).
3.2.P.8.6 Procedures for disposal of unused product and the handling of expired products should be detailed.

3.2.A. APPENDICES

3.2.A.1 Appendix 1:Evaluation of the safety of adventitious agents

3.2.R: Summary lot protocols

MODULE 4: NON CLINICAL STUDY REPORTS
Where applicable submit Non clinical study reports

MODULE 5: CLINICAL STUDY REPORTS

5.1 Table of Contents of Module 5

5.2 Tabular Listing of All Clinical Studies

5.3 Clinical Study Reports

5.3.1 Clinical indications/clinical outcomes/adverse reactions
5.3.1.1 The clinical indication for use of the product should be provided.
5.3.1.2 Relevant clinical practice guidelines on the use of the product(s) should be specified.
5.3.1.3 There should be a procedure to obtain post product release data following the transplant or transfusion of product. Examples may include, but not be limited to, engraftment data or any adverse reaction of the donor or recipient following transplant or transfusion.
5.3.1.4 Details on the procedures for monitoring an adverse reaction should be provided (if applicable).